PTEN缺失导致胶质母细胞瘤蛋白酶体成瘾:一种新的治疗脆弱性
该研究通过对患者来源的胶质瘤干细胞(GSC)进行高通量药物筛选,发现GSC对蛋白酶体抑制剂卡非佐米高度敏感,其机制与PTEN缺失及PI3K/mTOR通路激活导致的蛋白合成增加和自噬缺陷相关。在3D类器官和原位模型中,蛋白酶体抑制可增加细胞死亡标志物、抑制肿瘤生长并延长小鼠生存,提示蛋白酶体抑制是PTEN缺失胶质母细胞瘤的潜在合成致死策略。
要点
- PTEN缺失导致GBM对蛋白酶体抑制剂敏感,与蛋白合成增加和自噬缺陷相关。
- 卡非佐米在GSC来源的3D类器官和原位模型中显示抗肿瘤活性并延长生存。
- PI3K/mTOR通路异常见于近50%的GBM,提示相当比例患者可能受益。
核心结论
- 蛋白酶体抑制是PTEN缺失且伴高蛋白合成率和自噬缺陷的胶质母细胞瘤的潜在合成致死治疗策略。
研究设计与样本
- 对患者来源的胶质瘤干细胞(GSC)进行高通量药物筛选,并对5个初筛命中药物进行剂量反应实验。
- 通过遗传学和药理学实验确认PI3K/mTOR对蛋白酶体抑制剂卡非佐米的依赖性。
- 利用蛋白质组学和生物信息学分析推导蛋白酶体抑制反应特征。
- 采用三维(3D)GBM类器官和临床前原位模型确定分子作用机制。
主要发现
- GSC对蛋白酶体抑制高度敏感,源于蛋白合成速率增加和自噬缺失,与PTEN缺失及PI3K/mTOR通路激活相关。
- 联合抑制自噬和蛋白酶体可增强细胞毒性,且特异性见于表达PTEN的GSC。
- 蛋白酶体抑制在3D GBM类器官中增加细胞死亡标志物,并抑制原位移植GSC小鼠的肿瘤生长、延长生存。
- PI3K/mTOR通路扰动见于近50%的GBM,提示相当比例肿瘤可能对蛋白酶体抑制敏感。
关键数值与推荐
- 高通量药物筛选后对5个初筛命中药物进行剂量反应实验。
- PI3K/mTOR通路扰动发生于近50%的胶质母细胞瘤。
临床怎么用
- 对于PTEN缺失或PI3K/mTOR通路激活的GBM,可考虑蛋白酶体抑制剂(如卡非佐米)作为潜在治疗选择。
- 联合自噬抑制可能增强蛋白酶体抑制剂对PTEN表达型GSC的细胞毒性,需进一步验证。
局限性
- 研究主要基于体外GSC和临床前模型,尚未在患者中验证疗效。
- 联合自噬抑制的增强细胞毒性仅见于表达PTEN的GSC,适用人群需明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) is the most common primary brain tumor in adults with a median survival of approximately 15 months; therefore, more effective treatment options for GBM are required. To identify new drugs targeting GBMs, we performed a high-throughput drug screen using patient-derived neurospheres cultured to preferentially retain their glioblastoma stem cell (GSC) phenotype. METHODS: High-throughput drug screening was performed on GSCs followed by a dose-response assay of the 5 identified original "hits." A PI3K/mTOR dependency to a proteasome inhibitor (carfilzomib), was confirmed by genetic and pharmacologic experiments. Proteasome Inhibition Response Signatures were derived from proteomic and bioinformatic analysis. Molecular mechanism of action was determined using three-dimensional (3D) GBM-organoids and preclinical orthotopic models. RESULTS: We found that GSCs were highly sensitive to proteasome inhibition due to an underlying dependency on an increased protein synthesis rate, and loss of autophagy, associated with PTEN loss and activation of the PI3K/mTOR pathway. In contrast, combinatory inhibition of autophagy and the proteasome resulted in enhanced cytotoxicity specifically in GSCs that did express PTEN. Finally, proteasome inhibition specifically increased cell death markers in 3D GBM-organoids, suppressed tumor growth, and increased survival of mice orthotopically engrafted with GSCs. As perturbations of the PI3K/mTOR pathway occur in nearly 50% of GBMs, these findings suggest that a significant fraction of these tumors could be vulnerable to proteasome inhibition. CONCLUSIONS: Proteasome inhibition is a potential synthetic lethal therapeutic strategy for GBM with proteasome addiction due to a high protein synthesis rate and autophagy deficiency.
引用
- Benitez JA, Finlay D, Castanza A, et al. PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma. Neuro Oncol. 2021. PMID: 33428749. doi:10.1093/neuonc/noab001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。